Core Viewpoint - The company is actively addressing the market demand arising from an aging population by developing and promoting elderly care products, while also focusing on collaboration with relevant authorities and institutions to adapt to policy changes [1]. Group 1: Product Development and Market Strategy - The company has established a presence in the elderly care product sector, specifically in adult incontinence care under the "Light Skin Care" brand and chronic wound care with silicone gel and foam dressings [1]. - Continuous product research and market promotion efforts are being undertaken to enhance the company's offerings in the elderly care segment [1]. Group 2: Collaboration and Policy Adaptation - The company emphasizes the importance of partnerships with civil affairs departments and elderly care institutions to ensure product alignment with relevant subsidy policies [1]. - Active progress is being made in channel integration with these institutions to facilitate the distribution of elderly care products [1]. Group 3: Future Planning and Capacity - The company plans to steadily expand its elderly care product categories and strengthen technological research and development based on market demand and its own advantages [1]. - Capacity planning will be conducted in a reasonable manner according to market conditions [1].

（文章来源：证券日报） 证券日报网1月26日讯 ，稳健医疗在接受调研者提问时表示，2026年开年，公司召开了面向全集团的战 略宣贯大会，大会以"产品领先，卓越运营，品牌向上，数智赋能"为主题，向全体员工明确未来三年战 略方向与2026年经营计划。公司始终坚持医疗业务和消费品业务同步发展，未来将保持战略定力，持续 深耕主业，走高质量发展之路。在业绩目标方面，收入端将朝着股权激励设定的目标持续努力。盈利能 力方面，两大主业持续通过产品创新迭代、优化产品结构、提升渠道管理质量、降本增效、提升投放效 率、加强品牌建设等措施，稳步提升盈利水平。面向2026年，公司上下众志成城，信心满满，将努力沿 着既定战略目标持续努力。中长期来看，公司坚持长期主义发展理念，公司一直重视保障股东投资利 益，希望通过良好的经营成绩及稳定的分红政策回报股东的长期支持。 ...

证券日报网1月26日讯 ，稳健医疗在接受调研者提问时表示，公司重视股东回报，上市后每年坚持现金 分红，分红金额占归母净利润比例也在逐年提升。截至2025年中期，公司累计现金分红28.8亿元，回购 股份支付现金6.9亿元，两项合计占首发募集资金净额的100.3%。未来，公司将根据每年的利润情况、 企业成长性和战略发展计划综合评估分红比例，努力保持稳定的分红水平。 （文章来源：证券日报） ...

Group 1: Strategic Planning and Business Development - The company aims for high-quality development by focusing on both medical and consumer goods sectors, with a strategic theme of "product leadership, excellent operations, brand enhancement, and digital empowerment" for 2026 [1] - The company plans to enhance profitability through product innovation, optimizing product structure, and improving channel management [2] - The company emphasizes long-term development and aims to return stable dividends to shareholders [2] Group 2: Investment Highlights - The core investment value is based on five aspects: broad industry space, significant brand and product advantages, stable financial status, consistent dividend policy, and a commitment to long-term sustainable development [3] - The company maintains a low debt-to-asset ratio and has robust operating cash flow, ensuring financial safety [3] Group 3: Medical Sector Growth Drivers - The medical sector's growth strategy for 2026 focuses on "product leadership" and includes three key battles: product breakthroughs, channel expansion, and integration with newly acquired companies [4] - The company plans to enhance product value and expand overseas markets while achieving revenue growth targets set by equity incentives [4] Group 4: Overseas Business Development - The company has established a solid foundation in overseas markets, including Europe, Japan, South Korea, and Southeast Asia, and aims to enhance brand sales and market presence [5] - The focus will be on clinical and academic promotion, particularly in Southeast Asia and the Middle East, with significant investments in market education [5] Group 5: Product Planning for All-Cotton Era - In 2026, the All-Cotton Era will focus on six key areas: maternal and infant care, personal care, intimate apparel, home sleep products, outdoor clothing, and light sports [6] - The strategy emphasizes the core advantages of "cotton philosophy, quality genes, and medical background" to strengthen brand recognition [6] Group 6: Retail Strategy and Store Efficiency - The All-Cotton Era plans to enhance store quality and efficiency through existing store optimization and cautious new store openings [7] - Key initiatives include upgrading store images, enhancing membership services, and embracing new retail channels for integrated online and offline experiences [8] Group 7: Dividend Policy - The company prioritizes shareholder returns, maintaining annual cash dividends, with cumulative cash dividends reaching CNY 2.88 billion by mid-2025 [9] - Future dividend levels will be assessed based on annual profits, growth potential, and strategic development plans [9] Group 8: R&D and Competitive Advantages - The company adheres to a "product leadership" strategy, focusing on innovation and high-quality product development in both medical and consumer sectors [10] - As of mid-2025, the company holds 1,109 patents in medical consumables and 701 medical product registration certificates, ensuring a leading position in the industry [10]

Core Viewpoint - 中红医疗 plans to engage in low-risk financial investments and hedging activities in 2026 to enhance financial stability and mitigate risks associated with currency and commodity price fluctuations [1][2][3][5] Group 1: Financial Activities - 中红医疗 intends to use up to 2 billion RMB of idle funds to invest in low-risk financial products with a maximum investment period of 36 months [5] - The company plans to conduct foreign exchange derivative transactions with a maximum balance of 500 million USD to manage currency risk, using its own funds [2][3][4] - The company aims to engage in commodity futures hedging with a total transaction amount not exceeding 50 million RMB, also funded by its own resources [2][3] Group 2: Governance and Approval - The board of 中红医疗 approved several proposals on January 19, 2026, which will be submitted for shareholder approval at the first extraordinary general meeting on February 5, 2026 [1][5] - The proposals include the use of idle funds for low-risk investments, foreign exchange derivative transactions, and commodity futures hedging, with related party transactions requiring abstention from voting by related shareholders [1][2]

Trading Information - As of January 19, 2026, Zhonghong Medical (300981) closed at 13.39 yuan, up 0.75%, with a turnover rate of 0.89% and a trading volume of 34,900 shares, amounting to 46.4462 million yuan [1] - On January 19, 2026, the net outflow of main funds was 2.9472 million yuan, while retail investors saw a net inflow of 0.9156 million yuan [1] Company Announcements - Zhonghong Medical announced it will provide a guarantee of 50 million yuan for its wholly-owned subsidiary, Zhonghong International (Hong Kong) Trading Co., Ltd., in a financing contract with China Construction Bank [1] - The guarantee period is three years from the maturity of the main debt, and the subsidiary's latest asset-liability ratio is 94% [1] - The total guarantee amount for the company and its subsidiaries is 735 million yuan, accounting for 13.43% of the latest audited net assets, with no overdue guarantees [1] Board Meeting Resolutions - On January 19, 2026, Zhonghong Medical held its 16th meeting of the fourth board of directors, approving several proposals including the use of idle funds for low-risk financial products and foreign exchange derivatives trading [2] - The proposals will be submitted for approval at the first extraordinary shareholders' meeting of 2026, scheduled for February 5, 2026 [2] Financial Management Strategies - The company plans to invest up to 2 billion yuan of idle self-owned funds in low-risk financial products with a maximum investment period of 36 months [5] - The investment will focus on R1 and R2 rated financial products issued by commercial banks, trusts, and other financial institutions [5] - The company aims to conduct commodity futures hedging with a maximum trading margin of 5 million yuan and a total trading amount not exceeding 50 million yuan, using self-owned funds [3][4] Foreign Exchange Derivatives Trading - Zhonghong Medical intends to engage in foreign exchange derivatives trading to mitigate exchange rate risks, with a maximum balance of 500 million USD at any time [3][4] - The trading will include foreign exchange forwards, swaps, and options, with the funds sourced from self-owned capital [4]

Core Viewpoint - The company,稳健医疗, is currently operating normally without any undisclosed major risks, and it is actively expanding its international business in the medical supplies sector while also exploring consumer goods [2]. Group 1: Company Performance - As of January 19, 2026, the stock price of the company closed at 36.55 yuan, with a slight increase of 0.55% and a trading volume of 61,600 shares, amounting to a total transaction value of 225 million yuan [1]. - The company has been asked about the potential decline in its 2025 annual performance, with the management indicating that the situation will be clarified in future periodic reports [2]. Group 2: International Business Expansion - The company has established a solid foundation in overseas markets, having entered multiple countries and regions including Europe, the United States, Japan, South Korea, and Southeast Asia, with a focus on enhancing its competitive advantages and increasing the sales proportion of its proprietary brands [2]. - The consumer goods segment, particularly the全棉时代 brand, is in a phase of gradual exploration for global brand expansion [2]. Group 3: Regulatory Environment and Market Opportunities - The company’s core product,全棉时代, aligns well with the national quality supervision policies that emphasize high-quality cotton products, presenting potential market opportunities and positive impacts on performance [2]. - The company plans to leverage product innovation, quality control, and brand promotion to enhance consumer perception of "全棉=高品质安全" and strengthen its brand advantage [2]. Group 4: Investor Communication - The company values communication with investors and is considering the suggestion of releasing performance reports to boost market confidence and effectively showcase its brand to core consumer groups [3]. - The management is open to evaluating the feasibility of regular performance updates as part of its investor communication strategy [3].

Core Viewpoint - Zhonghong Medical (300981) has announced a temporary shareholders' meeting to discuss various financial strategies, including low-risk investment products and foreign exchange derivatives [1] Group 1: Stock Performance - As of January 19, 2026, Zhonghong Medical's stock closed at 13.39 yuan, up 0.75% from the previous trading day [1] - The stock opened at 13.2 yuan, reached a high of 13.46 yuan, and a low of 13.2 yuan, with a trading volume of 46.4462 million yuan and a turnover rate of 0.89% [1] Group 2: Shareholders' Meeting - The first temporary shareholders' meeting for 2026 is scheduled for February 5, 2026, at the Beijing Economic and Technological Development Zone [1] - The agenda includes proposals for using idle funds for low-risk financial products, engaging in foreign exchange derivatives trading, and conducting commodity futures hedging business, which involves related party transactions [1] - The record date for shareholders is January 29, 2026, and online voting will be conducted through the Shenzhen Stock Exchange system [1]

Core Viewpoint - The company, Weigao Medical (300888), is currently operating normally and steadily, with no undisclosed major risks. Future performance for the year 2025 will be confirmed in subsequent periodic reports [1]. Group 1: Business Operations - The company has a solid foundation in its international medical business and is actively expanding into markets in Europe, America, Japan, South Korea, and Southeast Asia [1]. - The company is focusing on enhancing its competitive advantages by increasing the sales proportion of prominent categories and its own brands as part of its international supply chain development [1]. Group 2: Consumer Products - The overseas division of the company's consumer goods brand, All Cotton Era, is steadily testing the waters and will gradually promote the brand on a global scale [1].

Core Viewpoint - The company,稳健医疗, aims to enhance health, care for life, and protect the environment, striving to make the world a better place through its vision [1] Group 1: Company Overview - The company operates under two main brands: "winner稳健医疗" and "Purcotton全棉时代" [1] - Its product range includes wound care, infection protection, surgical consumables, personal care, home care, maternal and infant care, and home textiles and clothing [1] Group 2: Brand Strategy - The company plans to continuously convey brand value through appropriate channels [1] - There is a focus on enhancing the recognition and reputation of its two main brands [1]